Krystal Biotech, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Krystal Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $15.97M, a 623.23% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $13.51M, a 520.91% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $159.95M, a 420.20% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $2.21M, a 3914.55% increase year-over-year.
- Krystal Biotech, Inc. stock issued during period, value, new issues for fiscal 2024 was $32.40M, a 79.74% decline from fiscal 2023.
- Krystal Biotech, Inc. stock issued during period, value, new issues for fiscal 2023 was $159.91M, a 450.37% increase from fiscal 2022.
- Krystal Biotech, Inc. stock issued during period, value, new issues for fiscal 2022 was $29.05M, a 91.83% decline from fiscal 2021.
- Krystal Biotech, Inc. stock issued during period, value, new issues for fiscal 2021 was $355.63M, a 201.29% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $32.40M 10-K · filed 2026-02-17 | |
| 2024-03-31 | $15.97M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $159.91M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $13.51M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $159.95M 10-Q · filed 2024-11-04 | |
| 2023-03-31 | $2.21M 10-Q · filed 2024-05-06 | |
| 2022-12-31 | $29.05M 10-K · filed 2025-02-19 | |
| 2022-09-30 | $2.18M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $30.75M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $55.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $355.63M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $1.53M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $14.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $152.03M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $118.03M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $298.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $117.34M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $243.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $107.53M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $13.36M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $93.83M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $44.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $73.85M 10-K · filed 2020-03-10 | |
| 2018-09-30 | $9.49M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $4.00K 10-Q · filed 2019-11-04 | |
| 2018-03-31 | $10.00K 10-Q · filed 2019-11-04 | |
| 2017-12-31 | $42.45M 10-K · filed 2018-03-12 | |
| 2016-12-31 | $100.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |